Alle Storys
Folgen
Keine Story von Isotechnika Inc. mehr verpassen.

Isotechnika Inc.

Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic Rights to ISA247

Edmonton, Canada (ots/PRNewswire)

Isotechnika Inc. announced
today that the Company has signed an  agreement with Lux Biosciences,
Inc. of Jersey City, New Jersey granting  Lux Biosciences worldwide
rights to develop and commercialize Isotechnika's  lead drug, ISA247
for the treatment and prophylaxis of all ophthalmic diseases.
ISA247 is a novel calcineurin inhibitor currently being
investigated in  a Phase III trial for the treatment of moderate to
severe psoriasis and a  Phase IIb trial for the prevention of organ
rejection following  transplantation.
Under the terms of the agreement:
-  Lux Biosciences, Inc. will make upfront and milestone payments to
           Isotechnika. Assuming all development milestones are achieved, the
           amount of this deal will be $32,700,000 USD with Isotechnika
           receiving an upfront payment of $3 million USD.
        -  Lux Biosciences, Inc. will pay Isotechnika royalties based on a
           percentage of net sales.
        -  Lux Biosciences, Inc. has exclusive worldwide marketing rights of
           ISA247 for all ophthalmic indications.
        -  Lux Biosciences, Inc. would be responsible, at its sole expense,
           for pre-clinical and clinical development, registration, and
           marketing of ISA247 for all ophthalmic indications.
        -  Isotechnika will be providing input on clinical trial design and
           will be reviewing and consulting on all regulatory filings.
        -  A Joint Steering Committee ("JSC") with equal membership from
           Isotechnika and Lux Biosciences, Inc. will be formed to oversee
           the development and commercialization of all ophthalmic
           indications.
"This agreement reconfirms the versatility of ISA247 as a multi-
platform technology," stated Dr. Randall Yatscoff, Isotechnika's
President  and Chief Executive Officer. "Lux Biosciences' team has
extensive  experience in this area and we are extremely pleased to
have them as a  partner. We believe this agreement provides us with
another opportunity to  optimize shareholder value."
Dr. Ulrich Grau, Lux Biosciences' President and CEO comments, "We
are  delighted to be able to partner ISA247 for ophthalmic
indications, and I  commend Isotechnika for its great efforts behind
its flagship molecule. We  are highly impressed with the emerging
profile of ISA247 that combines  efficacy with superior safety. We
believe that ISA247 has the potential to  become the calcineurin
inhibitor of choice with great potential in several  indications,
including ophthalmic indications."
Dr. Randall Yatscoff will chair a web cast this morning to provide
an  overview of the agreement. The web cast will take place at 9:00
a.m. ET/ 7: 00 a.m. MT. All interested parties can access the live
web cast (listen  only mode) by accessing
http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID(equal
sign)1497760  or through the home page of the Company's corporate Web
site at  www.isotechnika.com.
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in  medicinal chemistry and immunology, the Company is
focused on the discovery  and development of novel immunosuppressive
therapeutics that are safer than  currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug  candidates for
treatment of autoimmune diseases and for use in the  prevention of
organ rejection in transplantation. Isotechnika looks to  become the
leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 is an immunosuppressant
currently  in an extension protocol of a Canadian Phase III human
clinical trial for  the treatment of moderate to severe psoriasis. In
addition, ISA247 has  successfully completed a Phase IIa trial for
kidney transplantation. The  Company also has an additional
immunosuppressive compound in its drug  pipeline, TAFA93 which is in
Phase I.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found  at www.isotechnika.com.
About Lux Biosciences Inc.
Founded in 2005, Lux Biosciences is a privately held biotechnology
company dedicated to the identification, optimization, development
and  commercialization of products for the treatment of ophthalmic
diseases. The  company has assembled a portfolio of product
candidates based on compounds  with demonstrated utility in
non-ophthalmic indications that offer  potential to address major
market opportunities in the ophthalmic field.  ISA247, the most
advanced of these, is expected to enter pivotal clinical  trials for
the treatment of uveitis by early 2007 and additionally offers a
pipeline of other potential product applications. More information on
Lux  Biosciences can be found at www.luxbio.com .
Forward-Looking Statements
This press release may contain forward-looking statements.
Forward-  looking statements, including the Company's belief as to
the potential of  its products, the Company's expectations regarding
the issuance of  additional patents and the Company's ability to
protect its intellectual  property, involve known and unknown risks
and uncertainties, which could  cause the Company's actual results to
differ materially from those in the  forward- looking statements.
Such risks and uncertainties include, among  others, the availability
of funds and resources to pursue research and  development projects,
the ability to economically manufacture its products,  the potential
of its products, the success and timely completion of  clinical
studies and trials, the Company's ability to successfully
commercialize its products, the ability of the Company to defend its
patents from infringement by third parties, and the risk that the
Company's  patents may be subsequently shown to be invalid or
infringe the patents of  others. Investors should consult the
Company's quarterly and annual filings  with the Canadian commissions
for additional information on risks and  uncertainties relating to
the forward- looking statements. Investors are  cautioned against
placing undue reliance on forward-looking statements.
Archived images on this organization are searchable through CNW
Photo  Archive website at http://photos.newswire.ca. Images are free
to accredited  members of the media. To request a free copy of this
organization's annual  report, please go to http://www.newswire.ca
and click on Tools for Investors.
Trades on Toronto Stock Exchange - (TSX:ISA)
www.isotechnika.com

Contact:

For further information: For Isotechnika: Dr. Randall Yatscoff,
President & CEO, Isotechnika Inc., Phone: +1-(780)487-1600 ext. 246,
Fax: +1(780)-484-4105, E-mail: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1(780)909- 4661, Fax: +1(780)-484-4105, E-mail:
sgillis-paulgaard@isotechnika.com; For Lux Biosciences: Ulrich Grau,
Ph.D., President and CEO, Lux Biosciences, Inc., Phone
+1-(917)518-2875, E-mail: ulrich.grau@luxbio.com; Joan Kureczka ,
Kureczka/Martin Associates, Phone: +1(415)-821-2413, E-
mail:jkureczka@comcast.net; Archived images on this organization are
searchable through CNW Photo Archive website at
http://photos.newswire.ca. Images are free to accredited members of
the media. To request a free copy of this organization's annual
report, please go to http://www.newswire.ca and click on Tools for
Investors.

Weitere Storys: Isotechnika Inc.
Weitere Storys: Isotechnika Inc.
  • 25.04.2006 – 15:21

    Isotechnika Signs Option Agreement for Topical Delivery Technology of ISA247

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an option agreement with Cellgate Inc. of Redwood City, California. This agreement allows Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ...

  • 20.03.2006 – 14:23

    Isotechnika Announces Preliminary 48 Week Clinical Data From the Phase III ISA247 Psoriasis Trial

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today preliminary 48 week clinical data obtained from its Phase III psoriasis and extension trials for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an additional 36 weeks or to ...

  • 17.03.2006 – 20:04

    Advisory - Isotechnika to Announce Clinical Data From Phase III Psoriasis Trial

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. will announce preliminary 48 week clinical trial data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, on Monday, March 20th at 8:00 a.m. EST/6:00 a.m. MST. Management will provide an overview of the preliminary 48 week Phase III data following the release ...